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Abstract. 
 
During apoptosis, caspases, a family of pro-
teases, disassemble a cell by cleaving a set of proteins.
Caspase-3 plays a major role in the disassembly of the
nucleus by processing several nuclear substrates. The
question is how caspase-3, which is usually cytoplasmic,
gains access to its nuclear targets. It was suggested that
caspase-3 is actively transported to the nucleus through
the nuclear pores. We found that caspase-9, which is ac-
tivated earlier than caspase-3, directly or indirectly in-
activates nuclear transport and increases the diffusion
 
limit of the nuclear pores. This increase allows caspase-3
and other molecules that could not pass through the nu-
clear pores in living cells to enter or leave the nucleus
during apoptosis by diffusion. Hence, caspase-9 con-
tributes to cell disassembly by disrupting the nuclear-
cytoplasmic barrier.
Key words: apoptosis • caspases • nuclear transport •
nuclear pores
 
Introduction
 
Apoptosis is cell suicide that is induced by various stimuli.
During apoptosis, the cell is disassembled by caspases, a
family of highly specific proteases (reviewed in Cryns and
Yuan, 1998; Thornberry and Lazebnik, 1998; Budihardjo et
al., 1999). Caspases are expressed constitutively as precur-
sors, which are activated by proteolytic processing. The
current model is that caspases are activated in a proteolytic
cascade, which includes initiator and effector caspases,
their inhibitors, and activators. Initiator caspases are acti-
vated by autoproteolysis, which is induced by binding to
specific activators. Each initiator caspase is activated in re-
sponse to a subset of cytotoxic stimuli. For example,
caspase-8 is activated by binding to DISC, a protein com-
plex, which is formed after stimulation of the death recep-
tors such as Fas and TNFR (reviewed in Ashkenazi and
Dixit, 1998). Caspase-9 is activated by binding to a complex
containing APAF-1 and cytochrome c, which is formed af-
ter a number of stimuli, including DNA damage. Impor-
tantly, cytochrome c has to be released from mitochondria
to participate in caspase-9 activation. The activated initia-
tor caspases activate effector caspases by proteolytic pro-
cessing. While initiator caspases are specific for each path-
way of apoptosis, the effector caspases are shared.
 
Initiator and effector caspases disassemble a cell by cleav-
ing a set of proteins. This processing results in dismantling of
cellular structures, disrupting metabolism, inactivating anti-
 
apoptotic activity of some proteins, and promoting pro-apop-
totic activity of others (reviewed in Thornberry and La-
zebnik, 1998; Porter, 1999). Remarkably, only a small frac-
tion of proteins is cleaved, indicating that cell disassembly is
highly efficient. Although it is not clear how the processing
of caspase substrates leads to cell death, it appears that
caspases target key components of cell structures and signal-
ing pathways. For example, during apoptosis, DNA is de-
graded by CAD, a DNAse, which is constitutively expressed
but is bound to its inhibitor ICAD/DFF45 in live cells (Liu
et al., 1997; Enari et al., 1998). Caspase-3 releases active
CAD by cleaving ICAD/DFF45 at only two sites (Sakahira
et al., 1998). In another example, caspases disassemble the
nuclear lamina, which is formed by polymers of lamins, by
cleaving these proteins at a single site (Lazebnik et al., 1995;
Orth et al., 1996; Takahashi et al., 1996).
 
Interestingly, caspase-3 is primarily cytoplasmic (Chan-
dler et al., 1998; Mancini et al., 1998; Zhivotovsky et al.,
1999; this study), while the complex of CAD with ICAD/
DFF45 is nuclear (Liu et al., 1998; Samejima and Earnshaw,
1998, 2000). Therefore, the question is, how does caspase-3
reach ICAD/DFF45 and its other nuclear targets? This
question is part of a larger problem, which is how the apop-
totic machinery, which is initially activated in the cytoplasm,
reaches the rest of the cell (Porter, 1999). It was suggested
that caspase-3 and perhaps other caspases are translocated
into the nucleus by active transport and that transport is re-
quired for apoptosis (Yasuhara et al., 1997; Kuwana et al.,
1998; Kohler et al., 1999).
 
Protein import and export is regulated by a complex ma-
chinery, which includes soluble components and nuclear
pores (reviewed in Mattaj and Englmeier, 1998; Nakielny
and Dreyfuss, 1999; Talcott and Moore, 1999). Nuclear
pores are gated channels composed of at least 50 proteins,
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many of which have not been characterized. Particles of
 
,
 
9 nM in diameter or globular proteins of less than 50–60
kD can enter the nucleus by diffusion, whereas larger ob-
jects should be actively transported. To be imported
through the nuclear pores, a protein should have a nuclear
localization signal (NLS)
 
1
 
 or be bound to an NLS-contain-
ing protein. The NLS is recognized by importins that form
a transport complex with the protein. The complex trans-
locates through the pores by a multi-step process, which
involves interactions between the complex and nuclear
pore components. Once in the nucleus, the transport com-
plex is dissociated upon binding of Ran-GTP to the im-
portins which release the protein. The dimeric complex of
importin and Ran-GTP is returned to the cytoplasm,
where Ran-GTP is converted into Ran-GDP by the subse-
quent action of Ran-GAP and Ran-BPs. Ran-GDP is
translocated into the nucleus as a complex with NTF2,
where it is regenerated into Ran-GTP by RCC1. Nuclear
export occurs similarly except that the exported protein
forms a complex with exportins and Ran-GTP. According
to this model, both import and export of proteins requires
a gradient of Ran-GTP in which a majority of the protein
is concentrated in the nucleus (Izaurralde et al., 1997).
To understand how the cytoplasmic apoptotic machin-
ery disassembles the nucleus, we investigated how cas-
pase-3 reaches its nuclear substrates. We found that
nuclear transport is inactivated after the activation of
caspase-9. Furthermore, caspase-9 directly or indirectly in-
creases the diffusion limit of nuclear pores, thereby allow-
ing caspase-3 and other molecules to enter the nucleus by
diffusion. Hence, caspase-9 promotes cell disassembly by
disrupting the nuclear-cytoplasmic barrier.
 
Materials and Methods
 
Cell Culture
 
MCF-7 cells (American Type Culture Collection) were maintained in
MEM media supplemented with 10% fetal bovine serum and nonessential
amino acids.
 
Induction of Apoptosis
 
Apoptosis in cells was induced with 50 
 
m
 
M cisplatin (Sigma-Aldrich), 1
 
m
 
M staurosporine, or 35 
 
m
 
g/ml TNF (Pharmingen) plus 10 
 
m
 
g/ml cyclo-
heximide (Sigma-Aldrich) as indicated. Apoptosis was monitored by re-
lease of cytochrome c and/or chromatin condensation.
 
Antibodies
 
Monoclonal antibodies to caspase-9 (1-2), caspase-8 (1-3), caspase-3 (4-1-
18), and caspase-7 (1-11) were described previously (Fearnhead et al.,
1998). Monoclonal antibody to caspase-3 used for immunofluorescence
was purchased from Transduction Laboratories. Rabbit polyclonal anti-
body to cytochrome c was prepared against cytochrome c and were affin-
ity purified on cytochrome c agarose. Antibodies to nuclear transport pro-
teins were purchased from Transduction Laboratories, except for RanGap
(Zymed Laboratories), mAB414 (Babco), and QE51 (Covance).
 
Immunofluorescence/Confocal Microscopy
 
Cells were grown on poly-
 
L
 
-lysine (Sigma-Aldrich)–coated glass cover-
slips, fixed in PBS containing 4% paraformaldehyde, permeabilized in
 
PBS containing 0.2% Triton and 0.5% BSA, and blocked with 2% BSA
and 2% normal goat serum. Primary antibody incubation was performed
according to the manufacturers’ protocols (exceptions are described be-
low) and was followed by secondary antibody conjugated to Alexa 594 or
Alexa 488 (Molecular Probes). Cells were stained with either 4
 
9
 
6-diami-
dino-2-phenylindole (DAPI) or propidium iodide and coverslips were
mounted using Prolong Antifade (Molecular Probes).
Monoclonal antibody to caspase-3 (0.5 
 
m
 
g/ml; Transduction Labora-
tory) was incubated with 1% acetone powder prepared from MCF-7 cells
for 1 h at room temperature, and clarified by centrifugation (10,000
 
 g
 
, 30
min) before using for immunofluorescence.
Images were acquired either on a Zeiss Axiophot microscope equipped
with a Photometrics SenSys cooled CCD camera using Image 2.0.5 soft-
ware (Oncor) or on a confocal laser scanning microscope (LSM410; Carl
Zeiss, Inc.).
 
Retroviral Gene Transduction
 
cDNAs of interest were cloned into a MarX-IV-neo (caspase-3 and
caspase-3–green fluorescent protein, GFP) or MarX-IV-puro (caspase-9)
retroviral gene transfer vector (Hannon et al., 1999). Retrovirus was pro-
duced by transfection into LinX-A packaging cells (L.Y. Xie, D. Beach,
and G.J. Hannon, unpublished observations). Media from transfected
LinX cells were supplemented with 8 
 
m
 
g/ml of polybrene, 10% FBS, and
nonessential amino acids and added to plates of MCF-7 cells. Plates were
centrifuged at 1,000 
 
g
 
 for 1 h, and then incubated for 12–18 h at 32
 
8
 
C. Me-
dia were then replaced after 2 d and infected cells were selected using
1 
 
m
 
g/ml puromycin or 600 
 
m
 
g/ml Geneticin for 4 or 7 d, respectively. In-
fected cell lines were maintained in MEM media supplemented with 0.5
 
m
 
g/ml puromycin or 300 
 
m
 
g/ml Geneticin.
 
GFP Oligomers, GFP-
 
b
 
-gal and NLS-GFP
 
Plasmids expressing GFP multimers were generated by cloning in frame
one or more GFP cDNAs into pEGFP (CLONTECH Laboratories, Inc.).
Plasmid expressing NLS-GFP was generated by subcloning the triplicated
SV40 T-Antigen nuclear localization sequence (DPKKKRKV)
 
3
 
 into
pEGFP. Plasmid encoding GFP-
 
b
 
-gal was generated by subcloning the
beta-galactosidase cDNA (Promega) into pEGFP.
 
Transient Transfections
 
Plasmids encoding GFP multimers, GFP-
 
b
 
-Gal, and GFP-NLS were
transfected into MCF-7 and MCF-7/C9DN cells using Fugene (Boeh-
ringer) according to the manufacturer’s instructions. The average trans-
fection efficiency was 30%. Apoptosis was induced 18 h after transfection.
 
Results and Discussion
 
Caspase-3 Translocates to the Nucleus
during Apoptosis
 
To investigate how caspase-3 reaches its nuclear substrates
during apoptosis, we used a breast carcinoma cell line
MCF-7, which does not express caspase-3 because of a mu-
tation in the caspase-3 gene (Janicke et al., 1998). As a re-
sult of the mutation, MCF-7 cells undergo apoptosis with-
out typical apoptotic nuclear changes, such as DNA
cleavage and condensation of chromatin into distinct
round particles, although some changes in chromatin
structure are detectable (Woo et al., 1998). Expression of
caspase-3 in MCF-7 cells restores both DNA fragmenta-
tion and chromatin condensation, providing a model sys-
tem to study the function of caspase-3 and its derivatives
(Janicke et al., 1998).
To monitor caspase-3 localization in live and apoptotic
cells, we decided to use a fusion of this protein with GFP,
which would eliminate potential problems associated with
the detection of proteins in apoptotic cells by immunofluo-
rescence. In particular, we were concerned that chromatin
condensation would make nuclear proteins less accessible
 
1
 
Abbreviations used in this paper:
 
 C9DN, caspase-9 dominant-negative
mutant; DAPI, 4
 
9
 
6-diamidino-2-phenylindole; GFP, green fluorescent
protein; NLS, nuclear localization signal. 
Faleiro and Lazebnik 
 
Caspases Disrupt the Nuclear-Cytoplasmic Barrier
 
953
 
to the antibodies. First, we investigated whether fusing
caspase-3 to GFP affects the function of this protease. We
used a retroviral gene transduction system (Hannon et al.,
1999) to make MCF-7 cell lines that express caspase-3
 
(MCF-7/C3) or a fusion of caspase-3 to E-GFP (MCF-7/
C3-GFP). Both caspase-3 and the fusion protein were ex-
pressed at levels comparable with the levels of caspase-3 in
other breast carcinoma cell lines (Fig. 1 A). Consistent
with the previous reports, we detected no caspase-3 in
MCF-7 cells (Fig. 1 A). Both MCF-7/C3 and MCF-7/C3-
GFP cells, but not the parental cell line, underwent typical
apoptotic chromatin condensation after treatment with
cisplatin, an anticancer drug that induces DNA damage
(Fig. 1 B). This indicated that the fusion to GFP did not af-
fect the ability of caspases-3 to induce nuclear changes of
apoptosis. This conclusion was also supported by the find-
ing that caspase-3 activity in extracts from apoptotic MCF-
7/C3 and MCF-7/C3-GFP cells was similar when measured
with DEVD-AFC, a peptide substrate for caspase-3 (data
not shown). Consistent with the previous reports (Krajew-
ska et al., 1997; Chandler et al., 1998; Mancini et al., 1998;
Zhivotovsky et al., 1999), caspase-3 was found primarily in
the cytoplasm in live cells, as was caspase-3-GFP (Fig. 1
C). Because caspase-3 and its fusion to GFP were similar
in their activity and localization, and because the fusion
protein could be visualized more reliably, we used cas-
pase-3 GFP in this study.
To confirm that caspase-3-GFP enters the nucleus dur-
ing apoptosis (Nakagawara et al., 1997; Posmantur et al.,
1997), we treated MCF-7/C3-GFP with cisplatin. We
found that caspase-3-GFP was no longer excluded from
the nucleus as detected by confocal (Fig. 2 A) and fluores-
cence (B) microscopy.
 
Caspase-3 Entry into the Nucleus Requires
Active Caspase-9
 
Apoptosis can be considered as a two-step process in
which the first step is a preparation for activating caspases
and the second is the activation and its consequences. We
asked whether caspase-3 translocation to the nucleus oc-
curs before activation of caspases or requires their activity.
Because we used a drug that damages DNA and because
apoptosis induced by DNA damage is often mediated by
caspase-9, we tested whether cisplatin kills MCF-7 cells
through the caspase-9 pathway. Treatment with cisplatin
released cytochrome c from mitochondria, indicating that
the caspase-9 pathway is initiated. The release of cy-
tochrome c correlated with translocation of caspase-3
into the nucleus and with typical chromatin condensation
(Fig. 2, B and C). To test whether caspase-9 activity is re-
quired, we used retroviral gene transduction to make a cell
line that expressed caspase-9 dominant-negative mutant
(C9DN) (MCF-7/C3-GFP/C9DN). This mutant prevents
the activation of caspase-9, but not the preceding steps of
apoptosis by competing with the endogenous caspase-9 for
binding to APAF-1. Consistent with previous reports
(Fearnhead et al., 1998), expression of C9DN did not af-
fect release of cytochrome c from mitochondria, but pre-
vented chromatin condensation (Fig. 2, B and D) and de-
tachment of the cells (data not shown). These observations
were consistent with the notion that cisplatin induces ap-
optosis in MCF-7 by activating caspase-9. The entry of
caspase-3-GFP into the nucleus during apoptosis was
blocked in MCF-7/C3-GFP/C9DN cells (Fig. 2, B and C),
indicating that caspase-9 activity is required for caspase-3
translocation. To determine whether caspase-3 activity or
Figure 1. Caspase-3 and caspase-3-GFP have similar function
and localization in MCF-7 cells. (A) Caspase-3 and caspase-
3-GFP are ectopically expressed in MCF-7 at levels similar to the
levels of caspase-3 in other breast carcinoma cell lines. Total cell
lysates prepared from MCF-7/C3, MCF-7/C3S (catalytically inac-
tive C3 mutant), MCF-7/C3-GFP, and MCF-7/C3S-GFP, and the
three indicated breast carcinoma cell lines were analyzed by im-
munoblotting using a monoclonal antibody to caspase-3. 50 mg of
lysate were loaded per lane. (B) MCF-7 cells that express either
caspase-3 or caspase-3-GFP undergo typical apoptotic chromatin
condensation. MCF-7, MCF-7/C3, and MCF-7/C3-GFP cells
were treated with 50 mM cisplatin for 12 h, fixed, stained with
DAPI to visualize chromatin, and scored by fluorescence micros-
copy for typical apoptotic chromatin condensation (indicated
with white arrows). 60% of cells expressing C3 and 64% of cells
expressing C3-GFP had typical apoptotic nuclear morphology,
which was not observed in MCF-7 cells. (C) Caspase-3 and
caspase-3-GFP have similar, cytoplasmic localization. Caspase-3
in MCF-7, MCF-7/C3, and MCF-7/C3-GFP cells was visualized
by fluorescence microscopy using a monoclonal antibody to
caspase-3, as described in Materials and Methods. As expected,
no caspase-3 was detected in MCF-7 cells. 
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processing were required for translocating this caspase, we
made cell lines that express various caspase-3 mutants, in-
cluding those with mutated catalytic cysteine, lacking
some or all processing sites (D
 
9
 
, D
 
28
 
, D
 
175
 
), or missing the
prodomain (M
 
1
 
 to D
 
28
 
). All the mutants translocated into
the nucleus similarly to caspase-3 (data not shown).
Hence, caspase-9 activity is required for caspase-3 to enter
the nucleus, whereas caspase-3 activity is not.
 
The Nuclear Transport Is Altered during Apoptosis
 
Previous reports suggested that caspase-3 is translocated
into the nucleus by active transport (Yasuhara et al.,
 
1997). Active transport typically concentrates a protein in
a particular compartment. However, we observed that
caspase-3 concentrations in the nucleus and cytoplasm
equilibrated. Therefore, we tested whether active nuclear
transport functions during apoptosis. A common assay to
monitor nuclear transport is to use GFP fused to three
copies of the SV40 T-antigen nuclear localization signal
(GFP-NLS), a soluble molecule that accumulates in the
nucleus of living cells (Roberts and Goldfarb, 1998). As
expected, GFP-NLS transiently expressed in MCF-7 cells
localized to the nucleus (Fig. 3, A and B). However, af-
ter treatment with cisplatin, GFP-NLS was distributed
throughout the cell. The release of GFP-NLS from the nu-
Figure 2. Caspase-3 translocates to the nucleus during apoptosis after caspase-9 activation. (A) Caspase-3 translocates into the nucleus
during apoptosis. MCF-7/C3-GFP cells were treated with 50 mM cisplatin for 8 h, fixed, and stained with propidium iodide (PI).
Caspase-3-GFP (GFP, green) and the nuclei (PI, red), were visualized by confocal microscopy. An arrow indicates a cell in which chroma-
tin begins to condense. Cells at later stages of apoptosis were difficult to observe because they shrink and detach. (B–D) Translocation of
caspase-3 into the nucleus during apoptosis requires caspase-9 activity. (B) MCF-7/C3-GFP and MCF-7/C3-GFP cells expressing a domi-
nant-negative mutant of caspase-9 (MCF-7/C3-GFP/C9DN) were treated with 50 mM cisplatin for 8 h. The cells were stained with DAPI to
visualize the chromatin and with a cytochrome c antibody to detect the release of this protein from mitochondria. GFP, DAPI, and cyto-
chrome c were visualized by fluorescence microscopy. White arrows indicate cells with released cytochrome c. (C) The rate of caspase-3
translocation into the nucleus is similar to that of chromatin condensation, and of cytochrome c release from mitochondria. MCF-7/C3-
GFP cells were treated and stained as in B, except cells were fixed at the indicated time. The incidence of C3-GFP translocation to the nu-
cleus, cytochrome c release, and change in chromatin structure was scored. (D) Dominant-negative mutant of caspase-9 (C9DN) prevents
C3-GFP translocation to the nucleus and chromatin condensation. MCF-7/C3-GFP and MCF-7/C3-GFP/C9DN cells were treated and
stained as in B. The incidence of C3-GFP translocation to the nucleus, cytochrome c release and change in chromatin structure was scored.
200–250 cells were counted for each measurement in all experiments. Average values of three experiments are presented in C and D. 
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cleus, like the equilibration of caspase-3 between the nu-
cleus and cytoplasm, was prevented in MCF-7 cells that
expressed caspase-9 dominant-negative mutant (Fig. 3, A
and B). These observations were consistent with the no-
tion that active transport is altered during apoptosis and
that this alteration is caused by the activity of caspase-9.
A prerequisite of active nuclear transport is the nuclear-
cytoplasmic gradient of Ran-GTP, in which a majority of the
protein is concentrated in the nucleus (Izaurralde et al.,
1997). We found that Ran, like GFP-NLS, was released from
the nucleus during apoptosis and distributed throughout the
cell (Fig. 3, C and D). As we observed with GFP-NLS, ex-
pression of the caspase-9 dominant-negative mutant pre-
vented Ran release. The dissipation of the Ran gradient and
the release of NLS-GFP were both consistent with the idea
that nuclear transport is inactivated in apoptosis. Hence,
caspase-3 would have to enter the nucleus by other means.
Caspase-3 could be actively exported from the nucleus
in living cells. In this case, inactivating nuclear transport
would lead to diffusion of caspase-3 into the nucleus. We
have not identified any obvious nuclear export signals
(NES) in caspase-3. Deletion of one motif that might be an
NES (I
 
20
 
 to D
 
34
 
, L. Englmeier, unpublished observations)
had no effect on caspase-3 localization (data not shown).
Therefore, we considered an alternative possibility, that
caspase-3 is excluded from the nucleus because of the dif-
fusion limit of the nuclear pores. Although caspase-3 is a
32-kD protein, which could diffuse into the nucleus, it is
conceivable that this caspase may form complexes with
other proteins, such as caspase inhibitors, or it may
 
 
 
oligo-
merize. We reasoned that if caspase-3 or caspase-3–con-
taining complexes are excluded because of their size, then
the diffusion limit of the nuclear pores would have to in-
crease for caspase-3 to enter the nucleus during apoptosis.
Figure 3. Nuclear-cytoplasmic barrier is disrupted during apoptosis. (A) Activation of caspase-9 leads to release of NLS-GFP during
apoptosis. MCF-7 and MCF-7/C9DN cells were transiently transfected with NLS-GFP. 18 h after transfection, the cells were treated
with 50 mM cisplatin for 10 h, fixed, and stained with a polyclonal antibody to cytochrome c and DAPI. White arrows indicate cells that
have released cytochrome c. Cells were scored for the release of cytochrome c, release of nuclear GFP, and change in chromatin struc-
ture (B). Note that expression of C9DN causes the decrease in the ratio between the cells that release cytochrome c and NLS-GFP. 200–
250 cells were counted for each measurement in all experiments. Shown is a representative of three experiments. (C) Activation of
caspase-9 leads to release of Ran from the nucleus. MCF-7 and MCF-7/C9DN cells were treated as in A, fixed, and stained with a mono-
clonal antibody to Ran, a polyclonal antibody to cytochrome c, and DAPI to visualize nuclei. The antibodies were visualized with
Alexa488-conjugated anti–mouse and Alexa596-conjugated anti–rabbit secondary antibodies. White arrows indicate cells with released
cytochrome c. Cells were scored for the release of cytochrome c, loss of nuclear Ran staining, and change in chromatin structure (D).
Note that expression of C9DN causes the decrease in the ratio between the cells that release cytochrome c and Ran. 200–250 cells were
counted for each measurement in all experiments. Shown is a representative of three experiments. 
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Nuclear Diffusion Limit Is Increased during Apoptosis
 
To determine whether the diffusion limit of nuclear pores
is altered during apoptosis, we transiently expressed GFP
oligomers ranging in size from a single GFP molecule (28
kD) to a GFP pentamer (140 kD). In addition, to test a
large molecule, we used a fusion of GFP with bacterial
 
b
 
-galactosidase, a soluble enzyme that is used as a tracer
or reporter in mammalian cells (GFP-
 
b
 
-Gal), although we
have no direct proof that GFP-
 
b
 
-Gal can freely diffuse in
the cell. Considering that-
 
b
 
-Gal is a tetramer, the pre-
dicted size of GFP-
 
b
 
-Gal is 
 
z
 
580 kD. As expected, in un-
treated cells, GFP was present throughout the cell,
whereas the GFP dimer (56 kD), GFP pentamer, and
GFP-
 
b
 
-Gal were excluded from the nucleus (Fig. 4, A and
B). In apoptotic cells, the GFP dimer and pentamer were
observed in both the nucleus and the cytoplasm, whereas
GFP-
 
b
 
-Gal remained in the cytoplasm. We also found that
GFP-
 
b
 
-Gal containing a nuclear localization signal re-
mained in the nucleus of apoptotic cells (data not shown).
Considering that the GFP oligomers are not substrates of
the nuclear transport machinery, it is reasonable to con-
clude that they enter the nucleus during apoptosis by dif-
fusion. Therefore, the permeability of the nuclear pores
increases during apoptosis, allowing even large proteins
and complexes to freely enter the nucleus during apopto-
sis. Hence, caspase-3 could enter the nucleus simply be-
cause the orifice of the nuclear pore increases.
It is conceivable that the nuclear pores remain intact but
the permeability is increased by perforation of the nuclear
membranes. However, the observations that nuclear mem-
branes remain intact during apoptosis argue against this
model (Wyllie et al., 1980; Allen, 1987). Consistent with
these reports, we found no evidence of membrane perfora-
tions in apoptotic MCF-7 cells that expressed C3-GFP
 
 
 
by
electron microscopy (data not shown). The observation
that the nuclear-cytoplasmic barrier remains impermeable
for GFP-
 
b
 
-Gal also argues against the perforation model.
Another possibility is that the collapse of the nuclear lam-
ina during apoptosis contributes to the increase in nuclear
pore permeability. Lamins, which form the lamina, are
thought to be cleaved by caspase-6, which is processed and
activated by caspase-3 (Slee et al., 1999). Consistent with
this, we found that lamin B1 remained intact in apoptotic
MCF-7 cells, in which the nuclear permeability is in-
creased, although it was processed in the cells that ex-
pressed caspase-3 or caspase-3 GFP (data not shown).
Therefore, cleavage of lamins is not required for the in-
crease in nuclear permeability during apoptosis.
 
Nuclear Pores Are Altered during Apoptosis
 
Because caspases disassemble a cell by processing their
substrates, and because the increase in nuclear permeabil-
ity required caspase activity, we reasoned that some com-
ponents of the nuclear transport machinery, either soluble
or insoluble, may be caspase targets. We found that none of
the tested proteins were cleaved in MCF-7 cells (Table I),
although two proteins, RanGap1 (a soluble component of
the transport machinery) and p270/TPR (a component of
the nuclear pore complex) were processed in MCF-7 cells
that expressed caspase-3. Because nuclear transport is dis-
rupted even without caspase-3, we concluded that process-
ing of these two proteins is not required for the increase in
nuclear permeability. We confirmed that nuclear pore pro-
tein NUP153 is cleaved in apoptotic HeLa cells (Buendia et
al., 1999), although we failed to detect it in MCF-7 cells
(data not shown), thus leaving open the question as to
whether processing of this protein is required for the in-
crease in nuclear permeability. It should be emphasized
Figure 4. Nuclear pore size
increases during apoptosis.
(A) MCF-7 cells were tran-
siently transfected with GFP
dimer (GFP2X), pentamer
(GFP5X), or a fusion of GFP
with  b-galactosidase (GFP-
b-gal). 18 h after transfection,
cells were treated with 50 mM
cisplatin for 10 h, fixed, and
stained with anti-cytochrome
c antibody and DAPI. White
arrows indicate cells with re-
leased cytochrome c. Cells
were scored for the release of
cytochrome c and the pres-
ence of GFP in the nucleus
(B). Three experiments were
performed with GFP23 and
GFP53 and two with GFP-
b-gal. 200–250 cells were
scored for each experiment.
Shown is a representative of
one such experiment. 
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that our inspection of the transport machinery was limited
by the available tools. We tested only 5 of the 
 
.
 
50 proteins
of the vertebrate nuclear pore, many of which have not
been characterized (Doye and Hurt, 1997; Talcott and
Moore, 1999). This leaves open the possibility that other
nuclear pore complex components are caspase targets and
their processing causes an increase in nuclear permeability.
For example, deficiency in yeast nup188 and nup170 results
in an increase of the nuclear permeability (Shulga et al.,
2000), suggesting vertebrate homologues of these proteins
as potential targets of caspases. Considering that caspases
usually target the key elements of a system or structure, the
putative caspase substrates in the nuclear pore are likely to
be critical to the pore function in living cells.
Since the inspection of the nuclear pore components
provided no clues for the increase in the permeability, we
considered several speculative mechanisms. One specula-
tion was that caspase activity leads to removal of the cen-
tral plug of the nuclear pore, which would explain the in-
crease in the nuclear permeability. To test this possibility,
we used antibodies to p62, a component of the plug (Tal-
cott and Moore, 1999). As expected, the antibody detected
nuclear pores in untreated MCF-7 cells, which appeared as
a typical nuclear rim, whereas hardly any nuclear rim was
detected in apoptotic cells (Fig. 5 A). We found that p62 is
intact in apoptotic cells as detected by immunoblotting
and reasoned that this protein may become soluble if the
plug is removed. However, we found that p62 detectable
by immunoblotting remained with the nuclear fraction of
both living and apoptotic cells during cell fractionation
(data not shown). Furthermore, a monoclonal antibody
114 (mAb114)
 
 
 
(Davis and Blobel, 1987), which detects
several nuclear pore proteins in the plug and beyond, also
failed to detect nuclear pores in apoptotic cells (Fig. 5 B),
arguing against the plug hypothesis and suggesting that
many pore proteins are affected. The failure to detect the
proteins may be due to a modification of the epitopes in
apoptotic cells or a failure of the antibodies to access
them. Interestingly, a fusion of nuclear pore membrane
 
protein POM121 with GFP was reported to be less detect-
able in apoptotic cells (Imreh et al., 1998), consistent with
some changes in the nuclear pores other than a change in
accessibility of the epitopes. Hence, it appears that some
alterations in nuclear pores accompany the increase in
their permeability during apoptosis, although what these
changes are remains to be determined.
A practical implication of the disappearance of nuclear
pore staining during apoptosis may be in using this obser-
vation to identify apoptotic cells that, like MCF-7, do not
have typical apoptotic morphology. We found that nuclear
pores were hardly detectable by immunofluorescence dur-
ing apoptosis not only in MCF-7 cells, but also all other
cell lines that we tested (HeLa, Cos, U2OS, RKO, and
U87) (data not shown), indicating that the apparent disap-
pearance of the nuclear pore staining is a common phe-
nomenon.
 
Caspase-8 Requires Caspase-9 Activity to Disrupt the 
Nuclear-Cytoplasmic Boundary
 
A current view is that common apoptotic changes can be
induced by activating one of the several initiator caspases,
such as caspase-8 or caspase-9. Therefore, we tested
whether initiator caspases other than caspase-9 can inacti-
vate nuclear transport. Because caspase-8 can indirectly
activate caspase-9 (Li et al., 1998; Luo et al., 1998), we
evaluated the effect of caspase-8 activity not only in MCF-7
cells, but also in the cells that express the dominant-neg-
ative mutant of caspase-9 (MCF-7/C9DN). Apoptosis in
these cell lines was induced by TNF-
 
a
 
 in the presence of
cycloheximide, which, for unclear reasons, potentiates the
 
Table I. Proteolytic Processing of Nuclear Transport 
Components during Apoptosis
 
Protein MCF-7 cells
MCF-7 cells 
expressing caspase-3
 
Soluble components
Importin 
 
b
 
1N C N C
Transportin NC NC
Ran NC NC
RanBP1 NC NC
RanGAP1 NC C
RCC1 NC NC
NTF2 NC NC
CAS NC NC
Nuclear pore components
p62 NC NC
p153 ND NC
p175 NC NC
p214 NC NC
p270 NC C
 
MCF-7 and MCF-7/C3 were either left untreated or were treated with 50 
 
m
 
M cisplatin
for 12 h, which resulted in 
 
.
 
75% apoptotic cells as scored by chromatin condensation.
Cell lysates were analyzed by immunoblotting using monoclonal antibodies to nuclear
transport proteins. NC, not cleaved; C, cleaved; ND, not detected.
Figure 5. Nuclear pores in apoptotic cells are not detectable by
antibodies to nuclear pore proteins. MCF-7 were treated with 50
mM cisplatin for 10 h, fixed, and stained with DAPI to visualize
chromatin and with antibodies to nuclear pore protein np62 (A)
or monoclonal antibody 414, which reacts with multiple nuclear
pore proteins (B). White arrows indicate cells that have lost nu-
clear pore staining and have condensed chromatin. 
The Journal of Cell Biology, Volume 151, 2000 958
 
effect of TNF-
 
a
 
. As expected, treatment with TNF-
 
a
 
 re-
leased cytochrome c (Fig. 6 A) and processed caspase-8 in
both cell lines (Fig. 6 C). However, Ran was released only
from the nucleus of MCF-7 cells, but not of the cells that
expressed C9DN (Fig. 6, A and B), indicating that, in the
absence of caspase-3, caspase-8 alone could not change the
nuclear pore permeability, but required the activity of
caspase-9 or its substrates. The finding that caspase-8 fails
to process caspase-7, a substrate of caspase-9, in MCF-7/
C9DN cells (Fig. 6 C) leaves both possibilities open.
In summary, activation of caspase-9 during apoptosis in-
creases permeability of the nuclear pore, which allows cy-
toplasmic caspases to reach their nuclear substrates and
lets soluble proteins that are normally restricted to the nu-
cleus or cytoplasm to distribute throughout the cell.
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